

### **AMENDMENTS TO THE CLAIMS**

The following listing of the claims replaces all prior versions of the claims submitted in the application.

1-17. Canceled

18. (Currently amended) A biodegradable medicament formulation comprising:

(i) a carrier system comprising a biodegradable blood plasma protein, which has been dried by fluidized bed drying with retention of its properties, wherein said blood plasma protein is selected from the group consisting of thrombin, fibrinogen, albumin, and mixtures thereof, and wherein the carrier system is in the form of microporous granules with a particle size in the range from 20 to 500  $\mu\text{m}$ , and

(ii) an active ingredient selected from the group consisting of antibiotics, corticosteroids, antimycotics, neuroleptics, antiepileptics, steroid hormones, anticancer hormones, antirheumatics, and combinations thereof.

19. (Previously Presented) The medicament formulation of claim 18, wherein the carrier system is a solid which has been produced by compression of the granules.

20. (Previously Presented) The medicament formulation of claim 18, characterized in that it is in the form of a granule mixture of (i) granules of particles of the carrier system and (ii) granules of the active ingredient.

21. (Previously Presented) The medicament formulation of claim 18, characterized in that it is in the form of mixed granules containing both the biodegradable blood plasma protein and the active ingredient or the active ingredient combination thereof.

22. (Previously Presented) The medicament formulation of claim 18, characterized in that it is composed of mixtures of particles or granules which are formed of an internal core and an external layer, wherein the external layer has been formed by the blood plasma protein, and the internal core comprises an inert excipient.

23. (Previously Presented) The medicament formulation of claim 22, wherein the inert excipient is a carbohydrate selected from the group consisting of lactose and mannitol.

24. (Previously Presented) The medicament formulation of claim 18, characterized in that it is in the form of compact homogeneous micropellets with an average particle diameter in the range from 35 to 500  $\mu\text{m}$ .

25. (Previously Presented) The medicament formulation of claim 24, wherein the average particle diameter is in the range from 50 to 150  $\mu\text{m}$ .

26-28. Canceled

29. (Previously presented) The medicament formulation of claim 18, characterized in that it is employed for topical administration.

30. (Previously presented) The medicament formulation of claim 18, characterized in that it is employed for parenteral administration.

31. (Previously presented) The medicament formulation of claim 18, characterized in that it is employed for transdermal administration.

32-33. Canceled

34. (Previously presented) A process for producing the depot medicament formulation of claim 18 comprising:

(i) spraying the biodegradable blood plasma protein in the form of a solution, or suspension, or both into a fluidized bed installation, and

(ii) drying under mild conditions with retention of the properties.